首页|叶天士通络法治疗痹症特色用药规律研究

叶天士通络法治疗痹症特色用药规律研究

扫码查看
基于中医久病入络理论,通络法治疗痹症具有独特优势,故借助古今医案云平台、SPSS Modeler和中医药整合药理学研究平台v2.0对通络法治疗痹症的"病-证-症-方-药-靶"多维网络全方位进行深入研究.总结《临证指南医案》治疗痹症的"病-证-症-方-药"规律以及内在联系,梳理《临证指南医案》治疗痹症的常用通络法以及用药规律,解释不同通络法治疗痹症的物质基础和生物学机制,从病的层面为中医药治疗痹症处方选药提供临床依据,从证的层面为通络法治疗痹症的潜在药物发现及实验研究提供参考.
Research on the characteristic medication rules of Ye Tianshi Tongluo method for treating rheumatism
In particular,Arthralgia syndrome has a long course of disease,based on the theory that chronic diseases enter the collateral,The Tongluo method has unique advantages in treating arthralgia.Therefore,with the help of the ancient and mod-ern medical record cloud platform,SPSS Modeler,and the integrated pharmacology research platform v2.Oof traditional Chinese medicine,a comprehensive study is conducted on the multi-dimensional network of"disease syndrome syndrome formula drug target"of Tongluo method in treating arthralgia,summarizing the"disease syndrome formula drug"laws and internal connections of the"Clinical Guidelines Medical Record"in treating arthralgia,Sort out the commonly used meridian unblocking methods and medication patterns in the"Clinical Guidelines Medical Record"for treating Bi syndrome,explain the material basis and biologi-cal mechanisms of different meridian unblocking methods for treating Bi syndrome,provide clinical basis for selecting traditional Chinese medicine prescriptions for treating Bi syndrome from the disease level,and provide reference for potential drug discovery and experimental research of meridian unblocking methods for treating Bi syndrome from the syndrome level.

Ye TianshiClinical Guidelines Medical RecordBi syndromeDisease syndrome syndrome prescription drug targetData miningTCMIP v2.0

潘赐明、王诗琪、张书涵、李佩佩、吴元洁、张思源、武玉珠

展开 >

云南中医药大学基础医学院,云南昆明 650500

云南省南药可持续利用研究重点实验室,云南昆明 650500

安徽农业大学生命科学学院,安徽合肥 230036

安徽医科大学第一附属医院,安徽合肥 230022

安徽中医药大学,安徽合肥 230038

展开 >

叶天士 临证指南医案 痹症 病-证-症-方-药-靶 数据挖掘 中医药整合药理学

2024

四川中医
四川省中医药学会,四川省中西医结合学会,四川省针灸学会,四川省中医药科学院

四川中医

CSTPCD
影响因子:0.522
ISSN:1000-3649
年,卷(期):2024.42(8)